<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Atossa Therapeutics Reports Positive Safety Data
Image Overlay - Atossa Therapeutics Reports Positive Safety Data

Atossa Therapeutics Reports Positive Safety Data

Atossa Therapeutics Reports Positive Safety Data

Atossa Therapeutics has reported positive interim safety data from its Phase I clinical trial of nasal spray and COVID-19 drug candidate, AT-301. The drug is designed for at-home use to help curb COVID-19 symptoms and slow the infection rate – it is not intended for patients who require hospitalization. Yourway has an advanced direct-to-patient offering, where we deliver trial materials directly to and from patients. This personalized care approach has proven effective in increasing patient satisfaction and improving recruitment and retention rates, leading to cost savings, shorter development timelines and improved health outcomes.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?